ArticleAIDS (London, England)2025
Case study of PEPFAR funding cuts on HIV infections and deaths: reversing hard-won gains.
Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The age and sex dynamics of heterosexual HIV transmission in Zambia: an HPTN 071 (PopART) phylogenetic and modelling study.medRxiv : the preprint server for health sciences · 2026Article
- Sex-Specific Factors Influencing HIV Infection.Immunological reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using a validated HIV transmission model for Zimbabwe, we simulated January 2025 U.S. President's Plan for AIDS Relief (PEPFAR) funding cuts' impacts on HIV incidence and HIV-related deaths. We found extending funding cuts through 2030 would increase HIV incidence by 78% and add 85 000 infections, producing 25 000 additional HIV-related deaths. However, if PEPFAR reinstated funding within 12 months, much or all of this harm could be offset through more efficient resource allocation, specifically, reallocating funds for oral PrEP towards long-acting PrEP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.